In 2026, the adjustment plan for the "dual directory" of medical insurance and commercial insurance will be emphasized.

The adjustment of the medical insurance drug list is related to the medication security of the insured population and also affects the innovation and development of the pharmaceutical industry, attracting widespread attention. Which drugs can be applied to the list? Which drugs will be removed? On May 17th, the National Medical Insurance Administration interpreted the adjustment plan for the 2026 basic medical insurance drug list and commercial insurance innovative drug list. "Overall, the 2026 catalog adjustment continues to adhere to the positioning of 'basic medical insurance ensures basic needs,'" said Huang Xinyu, director of the Medical Services Management Department of the National Medical Insurance Administration. The adjustment plan highlights clinical value and patient benefits, and establishes a mechanism for connecting the commercial insurance innovative drug list and the medical insurance drug list to promote the construction of a multi-level medical security system.